Advanced Search:

NURO - NeuroMetrix

$4.31  -1.19 (-21.64%)

Updated: 09:06 May 23, 2022 EST

Accuracy AVG (AI)

N/A

Next Week
Trend's Accuracy (AI)

N/A

Equity Rank Position

Overall Rank Position

Innrs Rank

Now

21.34

This Week

21.07

This Qtr.

20.99

Next Qtr.

24.99

This Year

32.67

Buy Strength

NeuroMetrix's Position Within the Medical Instruments & Supplies Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

NEUROMETRIX - HISTORICAL DATA 6M

  • Last price

    $ 4.31

  • Daily change

    $ -1.19

  • Previous Close

    $ 5.5

  • Last Updated

    09:06 May 23, 2022 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
13.45 1.23 0.27 -0.96 -0.88

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
37.41 10.35 6.01 5.69 5.64

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
50% 55.76% 55.76% 55.76%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
4.7 -8.56% 5.14 -14.62% 6.02 -29.43% 8.53

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
N/A N/A 1.5 -1

NeuroMetrix Technical Analysis News

NeuroMetrix Stock Over 21% Down At Session Start Today

(VIANEWS) - Shares of NeuroMetrix (NASDAQ: NURO) fell by a staggering 21.64% to $4.31 at 10:46 EST on Monday, following the last session's downward trend. NASDAQ is falling 0.3% to $11,354.62, after three sequential sessions in a row of losses. This seems, up until now, a somewhat negative trend trading session today.NeuroMetrix's last close was $4.31, 88.88% below its 5...

At May 23, 2022, 9:47 am

Via News

NeuroMetrix

4B Gill Street
Woburn, MA 01801
United States
781 890 9989
http://www.neurometrix.com

Sectors: Healthcare
Industry: Medical Instruments & Supplies
F. Time Employees: 20
Description

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.

Corporate Governance

NeuroMetrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

NEUROMETRIX'S HOLDERS RANK

List of holders with stock participation in NeuroMetrix.